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Structural analysis of the 11b-hydroxysteroid dehydrogenase Nephropathies of any etiology tend to progress to end-
type 2 gene in end-stage renal disease. stage renal disease (ESRD) more or less rapidly over time
Background. Mutations in the 11b-hydroxysteroid dehydro- [1]. Hypertension is the major contributor in the progres-genase type 2 (11bHSD2) gene cause a rare form of low-renin
sion of renal failure in patients with renal disease bothhypertension leading to end-stage renal disease (ESRD) in
with and without proteinuria [2]. On the other hand, hy-some affected subjects. To date, no search for mutations in the
HSD11B2 gene was performed in a large population to obtain pertension per se is a cause of ESRD [3, 4]. The preva-
an estimate its prevalence. lence of hypertension among renal patients is high and
Methods. The HSD11B2 gene was analyzed in 587 subjects, increases with decreasing glomerular filtration rate (GFR)including 260 ESRD patients (either dialysis or transplanted)
[5]. One characteristic of hypertension associated withfor mutations in the exons 2 through 5 and corresponding in-
renal diseases is its exquisite salt dependency. Therefore,tronic regions by polymerase chain reaction (PCR) using appro-
priate overlapping primers, gel analysis by single strand confor- it is possible that a genetic predisposition to salt-depen-
mational polymorphism (SSCP), and sequencing of identified dent hypertension may either predispose to the develop-
migration variants.
ment of renal diseases and/or promote a more rapid lossResults. The prevalence of single-nucleotide polymorphisms
of GFR in patients suffering from renal disease. Thus,(SNPs) in ESRD patients and controls was 26%. The following
genetic variants were found among all subjects investigated: genes regulating renal sodium handling may play an im-
exon 2 T442G (Leu148/Val, N 5 70) and C470A (Thr156/Thr, N 5 portant role in patients suffering from ESRD.
67), exon 3 G534A (Glu178/Glu, N 5 69), and exon 5 C1274T The 11b-hydroxysteroid dehydrogenase type 2 (11bHSD2)
(Asp388/Asp, N 5 2). Four SNPs were identified in intron 4
is a member of the short-chain alcohol dehydrogenaseonly. In the control population, the prevalence of the variants
superfamily [6], localized in the endoplasmatic reticulumLeu148 and Thr156 was 14% each. Glu178 was 11%, while no
variants were found in exon 5. In ESRD patients, the preva- with a cytoplasmatic-oriented catalytic domain [7]. Its
lence of the variant Leu148 was 9%, and Thr156 was 8%. Glu178 main function is the protection of the mineralocorticoid
was 13%, while the Asp388 variant was 0.7%. In patients with receptor (MR) from promiscuous access of endogenousa short duration between the time of diagnosis of the renal
glucocorticoids (GCs) [8]. Such a protection is function-disease and the onset of ESRD, the prevalence of the Leu148
ally meaningful because the nonselective MR has theand Glu178 variants was higher than in subjects with slowly
progressing renal disease. The 11bHSD2 activity of all of these same in vitro affinity for its physiological substrate aldo-
SNPs is predictably unaltered. sterone and for the GC cortisol [9]. Normally, the
Conclusions. There is a high prevalence of SNPs of the 11bHSD2 protects the MR from occupation by cortisol,HSD11B2 gene, without causing exonic mutations generating
converting cortisol to the receptor inactive cortisonea 11bHSD2 enzyme with altered activity. Based on statistical
[8, 10]. The 11bHSD2 is preferentially found in cellsanalyses, the frequency of homozygosity for mutated alleles
of the HSD11B2 gene can be derived as ,1/250,000 when a expressing MR, such as the distal tubules [10–12].
Caucasian population is considered. Mutations in the gene of 11bHSD2 (HSD11B2) cause
renal sodium retention, urinary potassium wasting, and
low renin, low aldosterone life-threatening hypertension.
We and others have recently elucidated the molecular
basis of this syndrome, called apparent mineralocorticoid
excess (AME) [13–18]. In AME, an autosomal recessiveKey words: hypertension, genetics, single nucleotide polymorphism,
progressive renal failure, mutation, salt dependency. disorder, the deficiency of the 11bHSD2 enzyme allows
excess cortisol binding to the MR [19]. Recently, weReceived for publication January 13, 2000
reported on a form of low-renin hypertension in whichand in revised form April 17, 2000
Accepted for publication May 10, 2000 a gene mutation produces a mild deficiency in the
11bHSD2 enzyme but without other phenotypic featuresÓ 2000 by the International Society of Nephrology
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Table 1. Baseline demographic characteristics of the 587 subjects studied, subdivided by population groups
Control subjects (N 5 327) ESRD patients (N 5 260)
Healthy Hypertension Diabetes Dialysis Transplantation
N 162 128 37 102 158
Sex m/f 95/67 70/58 21/16 59/44 89/69
Age 49616 59617b 52621 64613b 48612c
BMI kg/m2 23.564.0 28.166.0b 25.964.6a 25.064.3a 24.964.6a
Blood pressure mm Hg
Systolic 129615 154621b 144623b 150626b 137614b,c
Diastolic 7869 90614b 8269a 81615 8668b,c
Data are mean 6 SD.
a P , 0.01, b P , 0.0001 vs. healthy controls
c P , 0.0001 vs. dialysis patients
that could lead to the diagnosis of AME, such as low (N 5 14), and Asia or Africa (N 5 6). Basic demographic
data, including current blood pressure, information onbirth weight, failure to thrive, hypokalemia, and nephro-
calcinosis [18], suggesting that an impaired 11bHSD2 associated diseases, and current medication, were ob-
tained for all subjects. For ESRD patients, the date ofactivity may play a role in the pathogenesis of essential
hypertension in some patients and that this may be genet- diagnosis of the renal disease, renal histology, time of
onset of ESRD, type of renal replacement treatment,ically determined. Moreover, heterozygosity for this rare
functional variant also has been shown to cause mild to age at transplantation, and other information were also
available. Genetic analysis in search of mutations in themoderate hypertension [20]. Patients with AME seem
at an increased risk to develop ESRD [21, 22]. A genetic gene encoding for the 11bHSD2 was performed in all
587 subjects, and the prevalence of identified mutationsassociation of a 11bHSD2 flanking microsatellite with
essential hypertension in blacks with ESRD was described was analyzed in patients with ESRD as compared with
control subjects.by Watson et al [23]; however, no structural correlate of
the gene itself was further analyzed. We observed an
DNA preparation and polymerase chainassociation between a polymorphic marker in exon 3
reaction analysis(G534A, Glu178/Glu) and young age at the time of occur-
rence of ESRD [24]. However, functional analysis of this Genomic DNA was isolated from peripheral blood
using the Nucleon BACC3 DNA extraction kit (Amer-variant in healthy subjects suggests a normal activity of
the 11bHSD2, as assessed by the ratio of urinary cortisol sham International, Buckinghamshire, UK). Mutation
detection was performed by single strand conformationalmetabolites (THF 1 5aTHF)/THE [25].
The real prevalence of mutations of 11bHSD2 in the polymorphism (SSCP) of polymerase chain reaction
(PCR) products from the exons 2 through 5 of thepopulation of patients with ESRD is presently unknown.
Therefore, this study aimed at establishing by structural HSD11B2 gene [24, 26] using the primers reported in
Table 2. Since a deletion of exon 1 was previously shownanalysis of the HSD11B2 gene first, whether mutations
in this gene are more prevalent in ESRD patients and to leave 11bHSD2 activity largely unaltered in intact
cells [27], exon 1 was not analyzed in the present study.thus whether subtle AME accounts for some cases of
ESRD, and second, whether mutations in the HSD11B2 All reactions were performed with 10 pmol of each
primer in a final volume of 50 mL, containing 2 mmol/Lgene causing a decreased activity of the enzyme in pa-
tients with renal diseases may promote a more rapid MgCl2 buffer, 0.5 mmol/L of each dNTP, and 1 unit of
AmpliTaq Gold polymerase (PE Biosystems, Fosterprogression to ESRD.
City, CA, USA). The DNA was amplified for 35 cycles
with denaturation at 968C for 20 seconds, annealing at
METHODS
638C for one minute, and extension at 728C for two
Subjects minutes. The nested PCR of exon 4 was performed using
1 mL PCR product, amplified for 25 cycles with denatur-Study subjects were 260 white patients with ESRD
(either dialysis or transplanted) from our Division of Ne- ation at 968C for 20 seconds, annealing at 558C for one
minute, and extension at 728C for two minutes.phrology and Hypertension (University Hospital of Berne,
Berne, Switzerland) and 327 white control subjects with-
Gel analysis and sequencingout renal diseases (Table 1). The geographic origin of
519 out of 587 subjects was the Swiss Germanic area, Polymerase chain reaction products were analyzed on
12% acrylamide gels containing 7.25% glycerol using awhile the remaining 68 consisted of subjects from the
North Mediterranean area (N 5 48), Eastern Europe two-buffer system. Four microliters of the PCR sample
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Table 2. Primers used in this study by the different population groups. The male to female
ratio was similar in all groups ranging from 55% of malesExon 2
Sense 59-CTGCTGGTGGCTTGGTTTG-39 in the hypertensive population to 59% of males in the
Antisense 59-AACTTCCAGTCCCCGTGTC-39 normal controls. Patients with hypertension or on dial-Exon 3
ysis were on average significantly older than the normalSense 59-AGGACACGGGGACTGGAAG-39
Antisense 59-GGGGGCTCCTTTTTGCTCC-39 controls. The body mass index (BMI) was higher in all
Exon 4 patient populations as compared with controls. SystolicSense 59-CAAGGGGCCGCATCGTGACTGT-39
blood pressure was significantly higher in all groups,Antisense 59-GGGAGCCAAAGCCAATTAGGACTG-39
Nested while diastolic blood pressure was significantly elevated
Sense 59-CCCACTGGAGCAAAAAGGAG-39 in the groups with hypertension, in diabetes mellitusAntisense 59-GAGCCAAAGCAAATTAGGAC-39
patients, or in transplanted subjects as compared withExon 5
Sense 59-CAGTCTGACCTTGCCA-39 normal controls.
Antisense 59-ATCGTAATGCTGGGGG-39 The overall prevalence of single-nucleotide polymor-
phisms (SNPs) in exons 2 through 5 and corresponding
introns of the HSD11B2 gene was 26%. A total of four
SNPs in exons 2, 3, and 5 of the HSD11B2 gene was
were loaded, and DNA was visualized by silver staining identified (Table 3). No molecular variant was found in
[24]. Sequence changes were detected by double-band exon 4. With the exception of the T442G (Leu148/Val)
shifts on the gel. Variants were purified using QIA-quick mutation, none of the other SNPs altered the predicted
PCR purification columns (Qiagen, Chatsworth, CA, amino acid sequence of the 11bHSD2 enzyme. The T442G
USA) according to the supplier and sequenced by Micro- (Leu148/Val) variant has been reported previously to have
synth (Balgach, Switzerland) on an ABI 373A automated an unaltered enzymatic activity [10, 28]. No mutations
sequencer (Applied Biosystems, Foster City, CA, USA) were found in intron 2 or 3, while 4 different SNPs were
using the same primers as for PCR. Obtained sequences discovered in intron 4 (Table 3). Furthermore, in all the
were compared with the HSD11B2 gene sequence (Gen- analyzed sequences of intron 4, we observed an addi-
Bank U27318). Identified variants were further analyzed tional variant (GC at nucleotide 128) that was also pres-
by restriction digest of PCR products according to stan- ent in PCR products with normal bands on SSCP. Some
dard methods. SNPs of the HSD11B2 gene tended to occur in cluster
(Table 3). The prevalence of identified SNPs also didStatistical methods
not differ between males and females. There was no
Values are expressed as means 6 SD. Statistical differ- difference in the distribution of SNPs of the HSD11B2
ences between means were assessed by the paired t-test gene between control subjects and ESRD patients, either
and the 2 3 2 contingency tables by the x2 test. taken together or analyzed separately for the dialysis
An estimate of the probability that, with a given preva- and transplantation subgroups (Table 3). The prevalence
lence, mutations are not detected was obtained by the of exonic SNPs did also not differ significantly among
Armitage Equation: normal control subjects, patients with hypertension, or
patient with diabetes mellitus without nephropathyZ 5 (N · p 2 1/2)/[N · p · (1 2 p)]22
(Fig. 1). The same was true when differences in these
where p is the assumed prevalence, N is the number of variants were analyzed between dialysis and transplanted
alleles, and N · p is the expected number of mutations. patients, with the exception of the G534A (Glu178/Glu)
The expected “disease” frequency for the target popula- variant, which showed a significantly higher prevalence
tion was calculated according to the Hardy–Weinberg in transplanted than in dialysis patients (P , 0.01 by x2;
Equation: Table 3).
The prevalence of molecular variants of the HSD11B2
p2 1 2 pq 1 q2 5 1 gene in patients with autosomal dominant polycystic kid-
ney disease (ADPKD) was extremely low (Fig. 1). Thiswhere p2 is the percent of homozygous dominant individ-
low prevalence was attributable to a low number of SNPsuals; p is the frequency of the dominant allele; q2 is the
in the exons as well as introns (Fig. 1). In ESRD patientspercent of homozygous recessive individuals; q is the
with a short duration between the time of diagnosis offrequency of recessive alleles; and 2pq is the percent of
the renal disease and the onset of ESRD (,5 years), theheterozygous individuals [18].
prevalence of the T442G (Leu148/Val) and G534A (Glu178/
Glu) variants was higher than in subjects with slowly
RESULTS progressing renal disease (17.1 vs. 6.9%, P , 0.01, and
Baseline demographic data of the subjects investigated 24.3 vs. 9.8%, P , 0.005 by x2, respectively). Both the
T442G (Leu148/Val) and G534A (Glu178/Glu) variantsin the present study are outlined in Table 1, subdivided
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Table 3. Identified single-nucleotide polymorphisms (SNPs) of the HSD11B2 gene in control subjects and patients with ESRD
Controls ESRD
All All Dialysis Transplanted
N 327 260 102 158
Exon 2
T442G (Leu148/Val) 46 (14%) 25 (9%) 10 (10%) 15 (9%)
C470A (Thr156/Thr) 46 (14%) 22 (8%) 9 (9%) 13 (8%)
T442G 1 C470A 46 (14%) 22 (8%) 9 (9%) 13 (8%)
Exon 3
G534A (Glu178/Glu) 35 (11%) 34 (13%) 9 (9%) 25 (16%)a
Intron 4
G!A nt22 1 (0.3%) 1 (0.4%) 1 (1%) 0
G!A nt24 1 (0.3%) 0 0 0
G!A nt302 (0.6%) 1 (0.4%) 1 (1%) 0
A!G nt38 68 (21%) 43 (16%) 18 (18%) 25 (16%)
Exon 5
C1274T (Asp388/Asp) 0 2 (0.7%) 2 (2%) 0
Multiple combinations
T442G 1 C470A 1 G534A 1 A!G nt38 29 (9%) 20 (7%) 9 (9%) 11 (7%)
No SNPs were identified in exon 4.
aP , 0.01 by x2 vs. dialysis patients
Fig. 1. Cumulative prevalence of identified
single-nucleotide polymorphisms (SNPs) of
the HSD11B2 gene among control subjects
(N 5 357) and patients with end-stage renal
disease (ESRD; N 5 260) by etiology. Abbre-
viations are: HTN, hypertension; DM, diabe-
tes mellitus; GN, glomerulonephritis; NS,
nephroangiosclerosis; IN, interstitial nephri-
tis; ADPKD, autosomal dominant polycystic
kidney disease. The “others” category in-
cludes vesicoureteral reflux, pyelonephritis,
Alport syndrome, Fabry’s disease, trauma, tu-
berculosis, dysgenesia/agenesia, and more.
Symbols are: (j) exon 2; ( ) exon 3; ( )
exon 5; (h) intron 4; *P , 0.0001 by x2 vs.
other ESRD or healthy controls.
were more prevalent in patients younger than 20 years different SNPs in the coding region of the HSD11B2
gene were identified, three were synonymous (unalteredat the onset of ESRD (20 vs. 8.6%, P , 0.001, and 40
amino acid sequence), and one was nonsynonymous butvs. 11.8%, P , 0.00001 by x2, respectively) as compared
conservative. The identified SNPs in the noncoding re-with the other ESRD patients.
gion are not predicted to affect splicing and thus are not
expected to alter 11bHSD2 function. Moreover, allele
DISCUSSION frequencies did not differ significantly between control
We have analyzed the HSD11B2 gene for association subjects and ESRD patients or between patients with
with ESRD in comparison with normal healthy controls, hypertension and ESRD. Thus, our data argue against
essential hypertensive patients, and diabetic patients. an important role of nonconservative mutations in the
The HSD11B2 is a logical candidate gene because (1) coding region of the HSD11B2 gene in a white ESRD
it has a role in maintaining sodium homeostasis, (2) a population. An association between the HSD11B2 locus
decreased activity of the 11bHSD2 enzyme results in and blacks with hypertensive ESRD was suggested by
sodium retention and plasma volume expansion, and (3) Watson et al using a polymorphic microsatellite marker
a salt-sensitive blood pressure increase occurs frequently [23]. However, these authors did not analyze the coding
in patients with chronic renal failure, contributing to region of the HSD11B2 gene itself, and therefore, the
significance of those findings in that specific ESRD popu-their high prevalence of hypertension. Although four
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lation remains unclear. Moreover, two similar analyses sume that the published sequence in Genbank is errone-
ous at this position. Second, some of the cSNPs ofwere unable to find an association between microsatellite
markers of HSD11B2 and hypertension; the first study HSD11B2 were more prevalent in patients with early
onset of ESRD (,20 years old) or with a renal diseaseinvolved more than 700 Caucasian hypertensive patients
[29], while the second preliminary report comprised a of short duration until the onset of ESRD (,5 years).
Because the transplanted patients were significantlycohort of hypertensive Afro-Caribbeans [30]. On the
other hand, our population included largely patients younger than the dialysis patients, this could explain the
higher prevalence of the G534A (Glu178/Glu) variant infrom the Swiss German area (88.4%), and therefore,
extension of these findings to other populations within transplanted than in dialysis patients, confirming our pre-
vious observation in a smaller group of ESRD patientsthe Caucasian ethnicity warrants some caution. In fact,
a significant difference in the frequency distribution of (46 dialysis and 61 transplanted) [24]. Although our ini-
tial focus is on the HSD11B2 gene, the possible linkageHLA-B44 haplotypes can be observed among three dis-
tinct European populations from Switzerland, the Neth- of these markers to other potential candidate genes of
relevance for renal diseases in this region is intriguing.erlands, and Slovenia [31], suggesting genetic heteroge-
neity. Third, in patients with ADPKD, the prevalence of SNPs
in HSD11B2 was extremely low (Fig. 1). These patientsSequence variation in human genes is largely confined
to SNPs. The SNPs most likely to influence disease are represent the only genetically homogeneous subgroup
of subjects investigated, and the likely explanation forthose occurring in the coding-region (cSNPs) and alter-
ing the amino acid sequence. A recent analysis of SNPs this observation would be the founder effect. In fact, 27
of the 30 patients with ADPKD and their ancestors forin coding regions of several human genes found that
less than one half the cSNPs comprise nonsynonymous several generations originate initially within 100 miles
from our center, although none of these subjects werecSNPs and that only 36% thereof represent nonconser-
vative cSNPs [32]. Moreover, in the large part, nonsynon- relatives. The only cSNP identified in this group was found
in a patient who migrated from a distant region. Fourth,ymous cSNPs are found at a frequency below 5% [32].
This observation is likely to reflect selection against dele- frequency and distribution of SNPs in patients with renal
diseases of rapid progression to ESRD (,5 years) didterious alleles during human evolution. The cSNPs of the
HSD11B2 gene detected had a minor allele frequency not differ as compared with other ESRD patients or with
the nondialysis population of hypertensive patients.ranging between 10 and 14%, in accordance with the
observed average allele frequency of 11% for other SNPs A moderately but clinically significant decrease in the
activity of 11bHSD2 in vivo could be determined eitherin candidate genes for hypertension [33].
The lack of detection of nonconservative mutations by (1) a circulating inhibitor of the enzyme [34], (2) the
presence of a mutated protein with partially reducedin our population could be due to the small sample size
analyzed. Nevertheless, according to the Armitage equa- activity, as it is the case for some cases of AME [18, 35],
or (3) a decreased expression of the wild-type enzyme.tion and for a probability ,5% of missing any significant
mutation causing a reduced 11bHSD2 enzymatic activity Indeed, many polymorphisms that affect biological func-
tion predictably occur outside of the coding region ofwith a total of 1174 alleles analyzed, the estimated preva-
lence of mutated alleles would be 0.3%. Thus, the sample genes. Noncoding DNA contains sequences important
for regulatory functions. There is, to date, no direct evi-size of this population is too small to detect significant
mutations in the HSD11B2 gene for an estimated preva- dence that this is the case for the HSD11B2 gene. How-
ever, indirect evidence has been suggested by a recentlence of 0.2% or less. Since AME is a recessive trait and,
thus, it is generally identified phenotypically only in the study, in which a subset of individuals with salt-sensitive
blood pressure was shown to have a decreased activity inhomozygous state, the expected “disease” frequency for
the target population calculated according to the Hardy– the 11bHSD2 enzyme in association with a polymorphic
microsatellite marker of the HSD11B2 gene [25]. Con-Weinberg equation is expected to be ,1/250,000, consid-
ering the frequency of the recessive allele of ,1/500. sidering the low prevalence of nonconservative cSNPs
in this gene, it is unlikely that the reduced 11bHSD2Therefore, it can be concluded that in this population the
rate of nonsynonymous, nonconservative cSNPs altering activity in this population is caused by mutations re-
sulting in altered amino acid sequence. Since the poly-the amino acid sequence and generating a 11bHSD2
enzyme with decreased activity is low. morphic microsatellite marker investigated is located in
intron 1, it is possible that this polymorphism could beSome findings of the present study deserve consider-
ation. First, we found a G!C transition at nucleotide 128 related to noncoding SNPs pivotal in control regions of
gene expression, as shown for other genes [36, 37]. Ofof intron 4 in all identified migration variants sequenced
in addition to the specific nucleotide polymorphisms particular interest is the recent description of polymor-
phism of the aldosterone synthase gene (CYP11B2) infound. Analysis of normal PCR products revealed the
same transition at nucleotide 128, and therefore, we as- association with hypertension [38]. Expression of the
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pressure as causal components of progression to end-stage renalCYP11B2 gene is regulated by angiotensin II. Angioten-
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